Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
BOSTON--(BUSINESS WIRE)--Jul. 26, 2017--
Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company
that is developing innovative and proprietary treatments for cramps and
spasticity associated with serious neurological diseases including
amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and
Charcot-Marie-Tooth (CMT), announced today that it will report its
financial results for the second quarter ended June 30, 2017 on
Wednesday, August 2, 2017 before the U.S. financial markets open. The
Company will host a conference call and webcast at 8:45 a.m. ET to
discuss second quarter 2017 financial results and provide a business
update. Individuals interested in participating in the call should dial
(855) 780-7202 (U.S. and Canada) or (631) 485-4874 (International).
A live webcast may be accessed in the Investors section of the Company's
website at www.flex-pharma.com.
Please log on to the Flex Pharma website approximately 15 minutes prior
to the scheduled webcast to ensure adequate time for any software
downloads that may be required. A replay of the webcast will be
available on Flex Pharma's website for three months.
About Flex Pharma
Flex Pharma, Inc. is a clinical-stage biotechnology company that is
developing innovative and proprietary treatments for cramps and
spasticity associated with the severe neurological diseases of ALS, MS
and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). Flex
Pharma was founded by National Academy of Science members Rod MacKinnon,
M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in
the fields of ion channels and neurobiology, along with Chair Christoph
Westphal, M.D., Ph.D.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170726005099/en/
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications